WO2010117455A3 - Anticorps monoclonaux humains protecteurs contre la peste bubonique - Google Patents

Anticorps monoclonaux humains protecteurs contre la peste bubonique Download PDF

Info

Publication number
WO2010117455A3
WO2010117455A3 PCT/US2010/001051 US2010001051W WO2010117455A3 WO 2010117455 A3 WO2010117455 A3 WO 2010117455A3 US 2010001051 W US2010001051 W US 2010001051W WO 2010117455 A3 WO2010117455 A3 WO 2010117455A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
human monoclonal
protective against
antibodies protective
against bubonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001051
Other languages
English (en)
Other versions
WO2010117455A2 (fr
Inventor
Kei Amemiya
Dimiter S. Dimitrov
Xiaodong Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research Institute of Infectious Diseases
Original Assignee
US Army Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research Institute of Infectious Diseases filed Critical US Army Medical Research Institute of Infectious Diseases
Priority to US13/260,413 priority Critical patent/US8722046B2/en
Publication of WO2010117455A2 publication Critical patent/WO2010117455A2/fr
Publication of WO2010117455A3 publication Critical patent/WO2010117455A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux entièrement humains qui reconnaissent spécifiquement l'antigène F1 ou V de Y. pestis et les épitopes reconnus par ces anticorps monoclonaux. L'invention concerne également des mélanges d'anticorps de la présente invention, ainsi que des procédés d'utilisation d'anticorps individuels ou leurs mélanges pour la détection, la prévention et/ou le traitement thérapeutique d'infections par la peste in vitro et in vivo.
PCT/US2010/001051 2009-04-08 2010-04-08 Anticorps monoclonaux humains protecteurs contre la peste bubonique Ceased WO2010117455A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/260,413 US8722046B2 (en) 2009-04-08 2010-04-08 Human monoclonal antibodies protective against bubonic plague

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21216609P 2009-04-08 2009-04-08
US61/212,166 2009-04-08

Publications (2)

Publication Number Publication Date
WO2010117455A2 WO2010117455A2 (fr) 2010-10-14
WO2010117455A3 true WO2010117455A3 (fr) 2011-04-14

Family

ID=42936768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001051 Ceased WO2010117455A2 (fr) 2009-04-08 2010-04-08 Anticorps monoclonaux humains protecteurs contre la peste bubonique

Country Status (2)

Country Link
US (1) US8722046B2 (fr)
WO (1) WO2010117455A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2460788C1 (ru) * 2011-07-28 2012-09-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Штамм гибридных культивируемых клеток животных mus musculus 13f8 - продуцент моноклональных антител, специфичных к капсульному f1 антигену yersinia pestis
TW201823460A (zh) * 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
CN117304313B (zh) * 2023-10-13 2024-03-05 青海省地方病预防控制所 一种特异性结合鼠疫耶尔森菌v抗原的全人源单克隆抗体
CN117756933A (zh) * 2023-12-13 2024-03-26 中国人民解放军军事科学院军事医学研究院 抗鼠疫耶尔森氏菌的重链抗体或其抗原结合片段及其相关生物材料与应用
CN117756932A (zh) * 2023-12-13 2024-03-26 中国人民解放军军事科学院军事医学研究院 抗鼠疫耶尔森氏菌LcrV抗原的重链抗体及其相关生物材料与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216696A1 (en) * 2004-08-23 2006-09-28 Goguen Jon D Rapid plague detection system
US20080166352A1 (en) * 2005-07-18 2008-07-10 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
US20080193465A1 (en) * 2005-08-16 2008-08-14 Dimitrov Dimiter S Human Monoclonal Antibodies that Specifically Bind Igf-II
US20090047293A1 (en) * 2005-10-25 2009-02-19 Novartis Vaccines And Diagnostics Srl Compositions Comprising Yersinia Pestis Antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220257D0 (en) * 2002-08-31 2002-10-09 Secr Defence Vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216696A1 (en) * 2004-08-23 2006-09-28 Goguen Jon D Rapid plague detection system
US20080166352A1 (en) * 2005-07-18 2008-07-10 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
US20080193465A1 (en) * 2005-08-16 2008-08-14 Dimitrov Dimiter S Human Monoclonal Antibodies that Specifically Bind Igf-II
US20090047293A1 (en) * 2005-10-25 2009-02-19 Novartis Vaccines And Diagnostics Srl Compositions Comprising Yersinia Pestis Antigens

Also Published As

Publication number Publication date
US8722046B2 (en) 2014-05-13
US20120114656A1 (en) 2012-05-10
WO2010117455A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2011071574A3 (fr) Anticorps monoclonaux dirigés contre la glycoprotéine du virus ebola souche soudan boniface
WO2010117455A3 (fr) Anticorps monoclonaux humains protecteurs contre la peste bubonique
WO2011160119A8 (fr) Anticorps contre gd2
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
HK1257730A1 (zh) 抗despr单克隆抗体用於癌症和中风的靶向疗法及成像
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
PH12016500859A1 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2011147982A3 (fr) Anticorps monoclonaux contre l'épitope de her2
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2011143624A3 (fr) Anticorps monoclonaux anti-cd47 humanisés et chimères
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2010083347A3 (fr) Macrocycles peptidomimetiques
WO2010096418A3 (fr) Molécules d'anticorps ayant une spécificité pour ox40 humain
CA2821268C (fr) Anticorps monoclonal humain ayant une specificite pour la proteine e du virus de la dengue de serotype 1 et utilisations de celui-ci
WO2010129033A3 (fr) Anticorps modifiés pour immunothérapie passive
WO2009126688A3 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
IN2012DN01328A (fr)
WO2010002478A3 (fr) Glycopeptide et son utilisation
WO2011088385A3 (fr) Compositions et procédés pour la détection du cancer
WO2011035205A3 (fr) Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
IL217746A (en) Human monoclonal antibody aganist s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
WO2009114560A3 (fr) Compositions et procédés pour le diagnostic et le traitement d’une infection à cytomégalovirus
WO2012021475A3 (fr) ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
WO2010086828A3 (fr) Anticorps monoclonaux agonistes anti-trkb

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761990

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13260413

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10761990

Country of ref document: EP

Kind code of ref document: A2